Written and reviewed by Kevin Nerway · Last verified 2 October 2026
Key Takeaways
- The benchmark Nifty 50 index declined 198.50 points to close at 22,421.95 on October 2, 2026.
- Pharmaceutical equities bucked the broader market downturn, led by a 13.04% surge in Krebs Biochem to 68.05.
- Morepen Labs rallied 6.14% to 133.72 on heavy trading volume exceeding 37.9 million shares.
- Equities traders faced heightened intraday volatility, reinforcing the importance of strict risk parameters during sector rotations.
Nifty Retrenches as Broad Market Selling Takes Hold
On October 2, 2026, the Nifty 50 index experienced a sharp pullback, closing down 198.50 points at 22,421.95. At PropFirmScan, our desk tracked this downward movement across Indian benchmark indices, noting how institutional order flow shifted out of broader equities during the afternoon session.
When benchmark indices drop nearly 200 points in a single session, funded traders holding long equity exposure face rapid equity curve erosion. Reviewing drawdown rules for equity traders is essential during such market shifts, as abrupt index drops can quickly breach daily loss parameters if leverage isn't strictly controlled. Utilizing our smart money reaction to Indian market flows data helps identify whether sell-offs are systemic or isolated to specific industry groups.
Selective Buying Lifts Pharma Constituents
Despite the baseline weakness across major indices, defensive sector flows provided targeted opportunities. Specifically, Indian pharmaceutical names attracted significant buying interest. Krebs Biochem surged 13.04% to close at 68.05, while Morepen Laboratories gained 6.14% to reach 133.72 on substantial turnover of 37,973.11 thousand shares.
Smaller market cap pharmaceutical counters also posted positive sessions: Vivimed Labs advanced 4.97% to 5.71, and Kilitch Drug gained 3.14% to finish at 220.00. This stark divergence between headline index weakness and stock-specific buying illustrates why active management and precise position sizing are vital when headline indices drop. Traders attempting to short equity baskets during sector rotations risk getting caught on the wrong side of sharp single-stock squeezes.
Market Impact Snapshot
| Asset / Equity | Direction | Confidence |
|---|---|---|
| Nifty 50 Index | Bearish | High |
| Krebs Biochem (KREBSBIO) | Bullish | High |
| Morepen Labs (MOREPENLAB) | Bullish | High |
| Vivimed Labs (VIVIMEDLAB) | Bullish | Medium |
| Kilitch Drug (KILITCH) | Bullish | Medium |
Risk Rules and Prop Trading Implications
For traders navigating funded accounts during equity index pullbacks, managing exposure around market benchmark turns is critical. A drop of 198.50 points in the Nifty can trigger stop-loss cascades in index futures and derivative products. Proprietary trading firms monitor your equity curve in real time; hitting your maximum daily drawdown during headline sell-offs is one of the quickest ways to fail an evaluation phase.
Before taking on new positions in volatile sessions, evaluating your strategy against challenge success rates during equities market phases provides clear context on how traders manage risk during drawdowns. If you are comparing funded trading programs that allow flexible stock and index trading, check our prop firm options suited for equities market conditions to verify daily limit calculations and hold rules. Traders looking to optimize their risk parameters can also use a dedicated lot size and margin calculator to ensure every trade fits within risk limits.
What to Watch in Coming Sessions
Moving forward, traders should monitor whether Nifty index support holds or if further liquidations hit broader equities. Key metrics to track include trading volume in outperforming sectors like pharmaceuticals, market breadth, and corporate announcements affecting mid-cap stocks.
Maintaining consistency and understanding firm-specific payout terms—such as checking our payout speed tracker and evaluating funded trader earnings potential—ensures you build a sustainable trading operation regardless of benchmark volatility. Traders seeking a tailored environment for their trading style can take our style-matched firm suggestions quiz.
Frequently Asked Questions
What caused the Nifty 50 index to fall on October 2, 2026?
The Nifty 50 index fell 198.50 points to close at 22,421.95 due to broad-based selling and institutional liquidation across benchmark equity components. Despite broad market pressure, select defensive sectors like pharmaceuticals experienced localized buying interest.
Which stocks outperformed during the Nifty pullback?
Pharmaceutical stocks bucked the broader negative trend on October 2, 2026. Krebs Biochem jumped 13.04% to 68.05, Morepen Labs rose 6.14% to 133.72, Vivimed Labs gained 4.97% to 5.71, and Kilitch Drug advanced 3.14% to 220.00.
How does Nifty volatility affect prop firm challenge accounts?
Sharp benchmark declines increase market volatility and slippage risk for index and stock traders. Traders using funded accounts must carefully manage lot sizing to ensure that intraday swings do not breach maximum daily loss limits set by their firm.
Are pharmaceutical equities expected to hold gains during index sell-offs?
While pharmaceutical stocks often attract defensive capital during market drawdowns, individual stock performance depends heavily on company-specific volume and earnings fundamentals. Traders should monitor trading volume and market breadth rather than assuming defensive